Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDEA.L Regulatory News (IDEA)

  • There is currently no data for IDEA

Pre-Close Trading Update

19 May 2020 07:00

RNS Number : 2669N
Ideagen PLC
19 May 2020
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION

19 May 2020

 

Ideagen PLC

("Ideagen," "the Company" or the "Group'')

 

Pre-Close Trading Update

 

Ideagen PLC (AIM: IDEA), a leading supplier of Information Management software to highly regulated industries, is pleased to provide an update on trading for the year ended 30 April 2020 and the outlook entering the new financial year.

 

The publication of the Company's full year results for the period to 30 April 2020 will be slightly later than normal this year and are expected to be published on or around the 22nd September 2020. This follows discussions with the Company's advisers and auditors and is due to the prevailing circumstances surrounding the COVID-19 pandemic and the practical difficulties that it will impose upon the audit process.

 

 

Trading Statement

 

The Board is pleased to report that trading for the year to 30 April 2020 was strong and results are expected to be in line with market expectations. This represents the Group's eleventh consecutive year of revenue and adjusted EBITDA* growth.

 

The Group expects to report revenue up 21% at approximately £56.6million as compared to £46.7million in the previous financial year. Adjusted EBITDA* is expected to be up 29% to approximately £18.5m on an IFRS16 basis and, on a like-for-like IAS17 basis, up 22% to approximately £17.5m.

 

The Board considers Annual Recurring Revenue (ARR) as its primary growth metric and the driver for long term value. ARR recognised during the year is expected to be £43.1m, representing an increase to 76% of total revenues from 67% the previous year. The ARR book as at 30 April 2020 was up 34% to approximately £48.7 million from £36.4 million, arising from both strong organic growth of approximately 19% on the previous year and acquired ARR from three acquisitions made within the year.

 

It is particularly pleasing to note that the organic growth was driven by 458 new customer logo wins across verticals such as Healthcare, Life Sciences, Financial Services and US Government, with new customers including the US Federal Reserve, SSE, Emirates and Corbus Pharmaceuticals. Investment appetite from new customers in sectors that have been more intensely impacted by the pandemic, including the Aviation and Manufacturing sectors, has as expected been slower. Reflecting the importance of the Group's software to our customers, there has been no material impact on the Group's existing customer relationships or the ARR book as a result of COVID-19.

 

Cash generated by operations was ahead of expectations at over 95% of adjusted EBITDA*, resulting in a gross cash balance of £8.2m and gross bank borrowings of £25.0m at the period end. Net bank debt at the year end of £16.8m was lower than anticipated and comfortably within banking covenants. As a result, the Group remains in a robust financial position.

 

Outlook

 

 

The Board reiterates the guidance it provided on 7 April 2020. Ideagen's software is considered business critical by our customers and this, together with a strong ARR book, gives the Board confidence that the £15m run rate revenue from the final quarter of previous financial year will continue as expected. The Group has also implemented a prudent cost reduction programme that has generated approximately £4m in annual savings.

 

In light of this, the Group believes it has the right financial model to meet market expectations for the current year and continues to intend to pay a dividend in respect of the financial year in line with its progressive dividend policy. The Group expects to declare this dividend at its full year results in line with its normal practice.

 

 

 

 

Ben Dorks, Chief Executive commented:

 

"We are pleased to report that despite the impact of COVID-19, the Group has continued to perform well in delivering yet another year of quality earnings growth underpinned by strong cash generation. The Group has now successfully transitioned to primarily a recurring revenue model and has quickly responded to the new and challenging business backdrop we all face. I would like to thank all our employees who have displayed great resilience and fortitude during these difficult times".

 

 

*Earnings before interest, tax, depreciation, amortisation, share based payments, acquisition costs and other exceptional items.

 

Enquiries:

Ideagen plc

01629 699100

David Hornsby, Executive Chairman

 

Ben Dorks, Chief Executive

 

Graeme Spenceley, Finance Director

 

 

 

 

 

 

finnCap Limited

 

020 7220 0500

Henrik Persson, James Thompson (NOMAD)

 

Alice Lane (ECM)

 

 

 

 

Canaccord Genuity Limited

 

020 7523 8000

Simon Bridges, Richard Andrews

 

 

About Ideagen plc

Ideagen is a UK-headquartered, global technology company quoted on the London Stock Exchange AIM market (Ticker: IDEA.L).

The Group provides software and services to organisations operating within highly regulated industries such as aviation, banking and finance and life science, with its main operational premises spread throughout the UK, EU, US, Middle East and SE Asia.

With an excellent portfolio of software products including Q-Pulse, Coruson, Pentana Audit and PleaseReview, Ideagen helps its clients reduce costs, improve operational efficiency, strengthen compliance and oversight and anticipate and manage every detail of risk.

Currently, more than 6,000 organisations use Ideagen's products including seven of the top 10 UK accounting firms, all of the top aerospace and defence companies and 75% of the world's leading pharmaceutical firms.

Ideagen's diverse and varied customer base includes many well-known, global brands such as British Airways, Aggreko, BAE, Ryanair, US Navy, KLM, BBVA, Bank of New York, Commerzbank, Meggitt, Heineken, Johnson Matthey, Haeco Group and European Central Bank. As well as this, Ideagen counts 180 hospitals across the UK and US amongst its client base.

For further information please visit www.ideagen.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTVVLFFBELLBBZ
Date   Source Headline
22nd Oct 201911:26 amRNSHolding(s) in Company
17th Oct 20193:32 pmRNSDirector/PDMR Shareholding
11th Oct 20197:00 amRNSAcquisition of Optima Diagnostics Limited
7th Oct 20193:29 pmRNSNotice of AGM
4th Oct 201910:45 amRNSExercise of Options, Issue of Shares and TVR
1st Oct 20197:00 amRNSExercise of Options, Issue of Shares and TVR
25th Sep 20197:00 amRNSRedland Acquisition Update - New Contract Wins
17th Sep 20197:00 amRNSDirector Dealing and Total Voting Rights
13th Sep 201912:08 pmRNSIssue of shares under the Share Incentive Plan
3rd Sep 20198:48 amRNSHolding(s) in Company
27th Aug 20192:21 pmRNSExercise of Options and Issue of Shares
14th Aug 20194:04 pmRNSIssue of New Shares under the Share Incentive Plan
30th Jul 201912:26 pmRNSHolding(s) in Company
22nd Jul 20194:20 pmRNSIssue of New Shares under the Share Incentive Plan
17th Jul 20197:00 amRNSPreliminary Results
19th Jun 201910:24 amRNSHolding(s) in Company
10th Jun 20197:00 amRNSAcquisition of Redland Solutions Ltd
30th May 20197:00 amRNSContract Award with New Tier 1 Airline Customer
15th May 20197:00 amRNSCapital Markets Day
14th May 20197:00 amRNSTrading Statement
12th Apr 20192:43 pmRNSDirector Dealings
11th Apr 20195:06 pmRNSIssue of Shares, Director Dealings and TVR
29th Mar 20197:00 amRNSExtension to 2018 Long Term Incentive Plan awards
25th Feb 20198:00 amRNSExercise of Options and Issue of Shares
30th Jan 201910:03 amRNSExercise of Options and issue of shares
28th Jan 20194:33 pmRNSIssue of new shares under the Share Incentive Plan
22nd Jan 20197:00 amRNSUnaudited Interim Results
21st Jan 20198:46 amRNSHolding(s) in Company
15th Jan 20197:00 amRNSAppointment of Joint Broker
14th Jan 20197:00 amRNSAcquisition of Scannell Solutions Ltd
11th Dec 20183:37 pmRNSIssue of Shares, Director Dealings and TVR
5th Dec 20182:54 pmRNSHolding(s) in Company
22nd Nov 201812:12 pmRNSHolding(s) in Company
21st Nov 20187:57 amRNSHolding(s) in Company
20th Nov 201812:04 pmRNSHolding(s) in Company
19th Nov 20185:56 pmRNSHolding(s) in Company
13th Nov 20187:00 amRNSTrading Update
30th Oct 20182:28 pmRNSResult of AGM
24th Oct 20182:35 pmRNSExercise of Options and Total Voting Rights
23rd Oct 201811:19 amRNSHolding(s) in Company
23rd Oct 20187:00 amRNS2018 Long Term Incentive Plan awards
12th Oct 20183:26 pmRNSHolding(s) in Company
10th Oct 20184:18 pmRNSHolding(s) in Company
8th Oct 201812:46 pmRNSIssue of Shares and Total Voting Rights
8th Oct 20187:00 amRNSPosting of Annual Report and Notice of AGM
5th Oct 20187:00 amRNSDirectors' Dealings
3rd Oct 20184:36 pmRNSExercise of Options & Total Voting Rights
2nd Oct 20184:38 pmRNSHolding(s) in Company
2nd Oct 20184:37 pmRNSHolding(s) in Company
28th Sep 20187:00 amRNSAcquisition of Morgan Kai Group Ltd

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.